Corporate Tech Investors

SR One Capital Management

SR One Capital Management is a corporate VC investing group that partners with companies that are a good strategic fit.

Venture Investor Overview

Venture Investor
SR One Capital Management
Status
Active
Investor Type
Corporate
Activity Level
127 transactions
Funds Raised
At least $500 million
Industry Focus
Biopharmaceutical
Healthcare Services
Life Sciences

Contact Information

Contact
Simeon George
Title
Chief Executive Officer
Mailing Address
161 Washington St. 500
Conshohocken, PA 19428
USA
Phone
(610) 567-1000
Website
www.srone.com
Email Address
[email protected]

Background Information

Overview
SR One assists high-potential healthcare companies in the United States and Europe at all stages of development, by contributing funding, knowledge, and networking. We operate on an evergreen basis, and have been making successful investments every year since 1985. SR One is a division of GlaxoSmithKline.
Profile
SR One Capital Management LinkedIn Company Profile
Social Media
SR One Capital Management Company Twitter Account
Company News
SR One Capital Management News
Facebook
SR One Capital Management on Facebook
YouTube
SR One Capital Management on YouTube
Last Transaction
12/4/2024

Transaction History

Our records indicate that SR One Capital Management invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Company
Date
Amount
Antag Therapeutics
12/4/2024
$84,600,000
Nomic
9/17/2024
$42,000,000
Renalys Pharma
7/18/2024
$38,000,000
Asceneuron
7/16/2024
$100,000,000
Zenas BioPharma
5/9/2024
$200,000,000
Mission Therapeutics
3/14/2024
$31,720,000
Alumis
3/7/2024
$259,000,000
Odyssey Therapeutics
12/5/2023
$101,000,000
Avalyn Pharma
9/27/2023
$175,000,000
Nimbus Therapeutics
9/6/2023
$210,000,000
Fore Biotherapeutics
8/25/2023
$75,000,000
ADARx Pharmaceuticals
8/9/2023
$200,000,000
ADARx Pharmaceuticals
1/20/2023
$46,000,000
Pulmocide
12/6/2022
$52,000,000
Rezo Therapeutics
11/17/2022
$78,000,000
Odyssey Therapeutics
10/13/2022
$168,000,000
Nimbus Therapeutics
9/12/2022
$125,000,000
MiroBio
6/29/2022
$97,000,000
Dren Bio
6/14/2022
$65,000,000
Ancora Biotech
6/9/2022
$60,000,000
Mineralys Therapeutics
6/8/2022
$118,000,000
Simcha Therapeutics
2/4/2022
$40,000,000
Nomic
12/10/2021
$17,000,000
HotSpot Therapeutics
11/30/2021
$100,000,000
ADARx Pharmaceuticals
9/14/2021
$75,000,000
ARS Pharmaceuticals
9/1/2021
$55,000,000
Arcellx
4/14/2021
$115,000,000
Design Therapeutics
1/28/2021
$125,000,000
Decibel Therapeutics
11/10/2020
$82,000,000
Dren Bio
10/19/2020
$60,000,000
Palleon Pharmaceuticals
9/18/2020
$100,000,000
Tranquis Therapeutics
7/10/2020
$30,000,000
HotSpot Therapeutics
5/22/2020
$65,000,000
Pandion Therapeutics
4/2/2020
$80,000,000
Design Therapeutics
3/25/2020
$45,000,000
MiroBio
10/7/2019
$34,000,000
Arcellx
10/4/2019
$85,000,000
Nkarta
9/6/2019
$114,000,000
TP Therapeutics
10/22/2018
$80,000,000
Decibel Therapeutics
6/20/2018
$55,000,000
Nimbus Therapeutics
6/6/2018
$65,000,000
Propeller Health
5/31/2018
$20,000,000
Constellation Pharmaceuticals
4/10/2018
$100,000,000
Macrolide Pharmaceuticals
4/3/2018
$20,000,000
Pandion Therapeutics
1/19/2018
$58,000,000
Atox Bio
12/5/2017
$30,000,000
Palleon Pharmaceuticals
10/5/2017
$47,600,000
eFFECTOR Therapeutics
7/25/2017
$38,600,000
Bicycle Therapeutics
6/2/2017
$51,400,000
TP Therapeutics
5/24/2017
$45,000,000
Progyny
5/3/2017
$10,000,000
ZappRx
4/21/2017
$25,000,000
Pulmocide
3/22/2017
$30,000,000
Propeller Health
10/21/2016
$21,500,000
Tioma Therapeutics
8/17/2016
$86,000,000
Morphic Holding
6/30/2016
$51,500,000
Spero Therapeutics
2/2/2016
$30,000,000
Navitor Pharmaceuticals
12/18/2015
$33,000,000
Constellation Pharmaceuticals
12/10/2015
$55,000,000
True North Therapeutics
12/3/2015
$40,000,000
Decibel Therapeutics
10/16/2015
$52,000,000
RaNA Therapeutics
7/23/2015
$55,000,000
Spero Therapeutics
6/8/2015
$30,000,000
CRISPR Therapeutics
4/30/2015
$64,000,000
Progyny
4/22/2015
Unknown
True North Therapeutics
4/7/2015
Unknown
ZappRx
4/2/2015
$5,600,000
Thrasos Therapeutics
4/1/2015
$21,000,000
River Vision Development
3/31/2015
$4,300,000
Nimbus Therapeutics
3/18/2015
$43,000,000
Macrolide Pharmaceuticals
3/5/2015
$22,000,000
Aileron Therapeutics
10/29/2014
$33,000,000
Atopix Therapeutics
10/8/2014
Unknown
eFFECTOR Therapeutics
9/30/2014
$4,180,000
Atox Bio
7/24/2014
$23,000,000
Navitor Pharmaceuticals
6/20/2014
$23,500,000
True North Therapeutics
6/17/2014
$22,000,000
Principia Biopharma
4/22/2014
$50,000,000
Spero Therapeutics
4/10/2014
$3,000,000
Alios BioPharma
4/8/2014
$41,000,000
River Vision Development
3/31/2014
$6,000,000
RuiYi
3/27/2014
$15,000,000
ZappRx
1/30/2014
$1,000,000
Aileron Therapeutics
11/18/2013
$30,000,000
True North Therapeutics
9/4/2013
Unknown
iPierian
9/4/2013
$30,000,000
Dicerna Pharmaceuticals
8/1/2013
$60,000,000
eFFECTOR Therapeutics
5/21/2013
$45,000,000
Blueprint Health
3/31/2013
$100,000
Aileron Therapeutics
1/14/2013
$12,000,000
Synovex
12/31/2012
$1,062,900
High Throughput Genomics
12/31/2012
$7,555,000
River Vision Development
12/13/2012
$17,000,000
AGTC
11/21/2012
$37,500,000
Principia Biopharma
10/29/2012
$12,500,000
Genocea Biosciences
10/10/2012
$30,000,000
IlluminOss Medical
9/28/2012
$28,000,000
RaNA Therapeutics
1/18/2012
$20,700,000
NeuroTherapeutics Pharma
12/31/2011
$12,000,200
Nimbus Therapeutics
6/28/2011
$24,000,000
HTG Molecular Diagnostics
6/13/2011
$16,200,000
Constellation Pharmaceuticals
6/6/2011
$15,000,000
SpringLeaf Therapeutics
5/12/2011
$15,000,000
Principia Biopharma
3/31/2011
$12,117,000
Genocea Biosciences
1/3/2011
$35,000,000
Semprus BioSciences
12/13/2010
$18,000,000
Dicerna Pharmaceuticals
10/22/2010
$4,000,000
iPierian
9/8/2010
$6,000,000
Constellation Pharmaceuticals
6/2/2010
$22,000,000
NeuroTherapeutics Pharma
5/20/2010
$43,000,000
CalciMedica
12/15/2009
$12,000,000
Alios BioPharma
6/11/2009
$32,000,000
Aileron Therapeutics
6/8/2009
$40,000,000
RuiYi
5/14/2009
$13,000,000
Genocea Biosciences
2/19/2009
$23,000,000
Melinta Therapeutics
2/4/2009
$25,000,000
CalciMedica
12/17/2008
$4,000,000
Metastatix
9/30/2008
$1,365,000
NuPathe
7/24/2008
$30,000,000
Metastatix
10/9/2007
$35,000,000
CalciMedica
7/31/2007
$1,530,000
Locus Pharmaceuticals
2/13/2007
$30,200,000
Morphotek
10/12/2006
$40,000,000
Metastatix
9/7/2006
$3,600,000
TorreyPines Therapeutics
6/30/2006
$6,364,000
Trinity Biosystems
6/30/2006
$21,000,000
Alere
6/30/2005
$6,750,000

 

Investor Contacts

Title
Name
Email & Social
Partner
Jill Carroll
  Jill Carroll LinkedIn Profile  Jill Carroll Twitter Account  Jill Carroll News  Jill Carroll on Facebook
Managing Partner
Rajeev Dadoo
  Rajeev Dadoo LinkedIn Profile  Rajeev Dadoo Twitter Account  Rajeev Dadoo News  Rajeev Dadoo on Facebook
Partner
Matthew Foy
  Matthew Foy LinkedIn Profile  Matthew Foy Twitter Account  Matthew Foy News  Matthew Foy on Facebook
Chief Executive Officer
Simeon George
  Simeon George LinkedIn Profile  Simeon George Twitter Account  Simeon George News  Simeon George on Facebook
General Partner
Deborah Harland
  Deborah Harland LinkedIn Profile  Deborah Harland Twitter Account  Deborah Harland News  Deborah Harland on Facebook

 

Funds

Our database includes the following fund closing(s) for SR One Capital Management. If we are missing funds, please contact us.

Fund Description
Vintage Date
Fund Amount
Fund I
11/19/2020
$500,000,000

 

Portfolio Companies

SR One Capital Management has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Tech Company
ADARx Pharmaceuticals
AGTC
Aileron Therapeutics
Alere
Alios BioPharma
Alumis
Ancora Biotech
Antag Therapeutics
Arcellx
ARS Pharmaceuticals
Asceneuron
Atopix Therapeutics
Atox Bio
Avalyn Pharma
Bicycle Therapeutics
Blueprint Health
CalciMedica
Constellation Pharmaceuticals
CRISPR Therapeutics
Decibel Therapeutics
Design Therapeutics
Dicerna Pharmaceuticals
Dren Bio
eFFECTOR Therapeutics
Fore Biotherapeutics
Genocea Biosciences
High Throughput Genomics
HotSpot Therapeutics
HTG Molecular Diagnostics
IlluminOss Medical
iPierian
Locus Pharmaceuticals
Macrolide Pharmaceuticals
Melinta Therapeutics
Metastatix
Mineralys Therapeutics
MiroBio
Mission Therapeutics
Morphic Holding
Morphotek
Navitor Pharmaceuticals
NeuroTherapeutics Pharma
Nimbus Therapeutics
Nkarta
Nomic
NuPathe
Odyssey Therapeutics
Palleon Pharmaceuticals
Pandion Therapeutics
Principia Biopharma
Progyny
Propeller Health
Pulmocide
RaNA Therapeutics
Renalys Pharma
Rezo Therapeutics
River Vision Development
RuiYi
Semprus BioSciences
Simcha Therapeutics
Spero Therapeutics
SpringLeaf Therapeutics
Synovex
Thrasos Therapeutics
Tioma Therapeutics
TorreyPines Therapeutics
TP Therapeutics
Tranquis Therapeutics
Trinity Biosystems
True North Therapeutics
ZappRx
Zenas BioPharma

 

 

 

 

Browse more corporate investors:

SpringCamp | SRIW

 

Share this article

 

About Our Corporate Tech Investor Database

The strategic investor data above is provided by VentureDeal.com, a leading provider of corporate tech investing transaction data.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.